| Expression pattern: |
UP |
| Associated gene: |
SLC7A11, AGO2, GPX4 |
| Associated microRNA: |
miR-654-3p |
| Biological function: |
promotes prostate cancer cell proliferation, migration, and invasion; suppresses ferroptosis; facilitates tumorigenicity in vivo |
| Molecular mechanism: |
ceRNA mechanism: circATP2C1 sponges miR-654-3p to increase SLC7A11 expression, leading to ferroptosis suppression |
| Biological pathway or process: |
ferroptosis (inhibits); proliferation (promotes); migration (promotes); invasion (promotes); metastasis (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
H
|
| Validation methods: |
Bioinformatics Analysis; RT-qPCR; FISH / smFISH; RNase R Treatment; Actinomycin D / DRB Stability Assay; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Transfection; CCK8; Transwell Assay; Wound Healing Assay; RNA-seq; ELISA; Western Blot; Electron Microscopy; In Vivo Animal Model; IHC (Immunohistochemistry); Survival Analysis |
| Clinical significance: |
high circATP2C1 expression is associated with lower overall survival and adverse clinicopathologic features (higher Gleason score, greater migratory capacity, more advanced lymph node metastasis stage) |
| Description: |
circATP2C1 is up-regulated in prostate cancer and mainly localized in the cytoplasm. It promotes proliferation, migration/invasion and tumor growth by acting as a ceRNA that sponges miR-654-3p, thereby upregulating SLC7A11 (and GPX4) to suppress ferroptosis; high expression correlates with worse overall survival and adverse clinicopathologic features. |
| Confidence score: |
0.8837 |